加拿大:放寬對已完成接種疫苗公民或永久居民入境限制
加拿大公佈,自7月5日起,對已完成接種經認證的新冠肺炎疫苗的公民或永久居民放寬入境措施,不必再進行隔離及第8天的病毒檢測,不過仍未準許其他外國人士入境。
但入境人士仍須遵循其他防疫要求,包括出發前和入境時接受病毒檢測、提供適當的隔離計劃、保留入境14天內的密切接觸名單,以及必須無症狀,並在公共場合保持佩戴口罩等。
目前加國官方認可的疫苗包括輝瑞(PFE.US)、莫德納(MRNA.US)、阿斯利康(AZN.US)和強生(JNJ.US)公司研製的新冠疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.